Subject Satisfaction With AbobutulinumtoxinA Treatment (DREAM)

Galderma

Status and phase: Completed; Phase 4

Conditions: Glabellar Frown Lines

Treatments: Biological: AbobotulinumtoxinA

Study type: Interventional

Funder types: Industry

Identifiers

NCT03687736

43USD1802

Details and patient eligibility

About

An interventional Phase 4 study to assess subject satisfaction with abobotulinumtoxinA treatment.

Full description

Following signature of informed consent and the screening process, eligible subjects were treated at the Baseline visit (Day 0) with abobotulinumtoxinA in the glabellar region. Subjects were re-treated at the Month 6 visit.

Enrollment: 120 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Moderate to Severe Glabellar Lines at Maximum Frown
• Understands study requirements and signs an informed consent

Exclusion criteria

• Known allergy to any component of study product
• Pregnant or breast feeding or intending to get pregnant during the study
• Botulinum toxin treatment in the face within 9 months

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

120 participants in 1 patient group

AbobotulinumtoxinA

Other group

Description:

Open-label

Treatment:

Biological: AbobotulinumtoxinA